Vorhyaluronidase Alfa
Vorhyaluronidase Alfa Uses, Dosage, Side Effects, Food Interaction and all others data.
A purified preparation of the enzyme recombinant human hyaluronidase. Vorhyaluronidase Alfa (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.
Hyaluronidase was first used in prescription products in the United States on 5 May 2004.
Hyaluronidase cleaves hyaluronic acid in the extracellular matrix to improve the dispersion of injectable drugs. Hyaluronidase has a long duration of action and a wide therapeutic window. Patients should be counselled regarding the risk of spread of localized infection, ocular corneal damage, and inactivation by intravenous administration.
| Trade Name | Vorhyaluronidase Alfa |
| Generic | Hyaluronidase (human recombinant) |
| Hyaluronidase (human recombinant) Other Names | Hyaluronidase (human recombinant), Hyaluronidase human recombinant, Hyaluronidase recombinant human, Hyaluronidase, human, Recombinant human hyaluronidase, Vorhyaluronidase alfa |
| Type | |
| Weight | 61000.0 Da |
| Protein binding | Data regarding the protein binding of hyaluronidase are not readily available due to hyaluronidase being inactivated in blood. |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Vorhyaluronidase Alfa is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.
Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography. Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.
Vorhyaluronidase Alfa is also used to associated treatment for these conditions: Congenital Immunodeficiency, Drug Extravasation, Early Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Parenteral rehydration therapy, Improving resorption of radiopaque agents, To increase percutaneous drug absorption
How Vorhyaluronidase Alfa works
Hyaluronidase cleaves hyaluronic acid at the glucosaminidic bond between C1 of glucosamine and C4 of glucuronic acid. Hyaluronic acid is a key component of the extracellular matrix. Injection of hyaluronidase with other fluids, drugs, or radiopaque agents improves the ability of these other compounds to permeate the extracellular space more easily.
Toxicity
Data regarding overdose of hyaluronidase is not readily available. In the even of an overdose, treat patients with symptomatic and supportive measures.
Food Interaction
No interactions found.Volume of Distribution
Data regarding the volume of distribution of hyaluronidase are not readily available due to hyaluronidase being inactivated in blood.
Elimination Route
Data regarding the absorption of hyaluronidase are not readily available due to hyaluronidase being inactivated in blood.
Half Life
Hyaluronidase has a half life of two minutes, but a duration of action of 24-48 hours due to its high potency.
Clearance
Data regarding the clearance of hyaluronidase are not readily available.
Elimination Route
After nonspecific proteolysis, the amino acids from protein drugs are reused for protein synthesis or further broken down and eliminated by the kidneys.
Innovators Monograph
You find simplified version here Vorhyaluronidase Alfa
